WH COVID Response Coordinator: J&J Pause Won’t Have ‘Significant Impact’ On Vaccine Rollout

Jeff Zients, President-elect Joe Biden’s pick to head the White House’s coronavirus response, speaks during a news conference at the Queen Theater on December 8, 2020 in Wilmington, Delaware. (Photo by Chip Somod... Jeff Zients, President-elect Joe Biden’s pick to head the White House’s coronavirus response, speaks during a news conference at the Queen Theater on December 8, 2020 in Wilmington, Delaware. (Photo by Chip Somodevilla/Getty Images) MORE LESS

White House COVID-19 Response Coordinator Jeff Zients said on Tuesday that federal health agencies’ recommendation to pause Johnson & Johnson’s COVID-19 vaccine would not cause a major disruption to the Biden administration’s vaccine rollout program.

“This announcement will not have a significant impact on our vaccination plan: Johnson & Johnson vaccine makes up less than 5 percent of the recorded shots in arms in the United States to date,” Zients said in a statement.

The official stated that the 300 million doses of Pfizer and Moderna’s vaccines secured by President Joe Biden meant there was “more than enough supply to continue the current pace of vaccinations of 3 million shots per day, and meet the President’s goal of 200 million shots by his 100th day in office.”

Earlier on Tuesday, the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) released a joint recommendation advising health care providers to stop administering J&J’s vaccine “out of an abundance of caution” while the agencies investigate the six reported cases of blood clots after the patients received the vaccine.

The agencies noted that the clots “appear to be extremely rare.”

During the FDA and CDC’s press conference on their announcement, acting FDA Commissioner Janet Woodcock said the pause was expected to last for “a matter of days.”

Shortly after the FDA and CDC made the recommendation, several states announced they would cease the distribution of J&J’s vaccine.

The pharmaceutical company said on Tuesday that it was “aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine.”

Dear Reader,

When we asked recently what makes TPM different from other outlets, readers cited factors like honesty, curiosity, transparency, and our vibrant community. They also pointed to our ability to report on important stories and trends long before they are picked up by mainstream outlets; our ability to contextualize information within the arc of history; and our focus on the real-world consequences of the news.

Our unique approach to reporting and presenting the news, however, wouldn’t be possible without our readers’ support. That’s not just marketing speak, it’s true: our work would literally not be possible without readers deciding to become members. Not only does member support account for more than 80% of TPM’s revenue, our members have helped us build an engaged and informed community. Many of our best stories were born from reader tips and valuable member feedback.

We do what other news outlets can’t or won’t do because our members’ support gives us real independence.

If you enjoy reading TPM and value what we do, become a member today.

Latest News
Comments
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Investigations Desk:
Reporters:
Newswriters:
Director of Audience:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: